AKBA
Akebia Therapeutics, Inc.
Drug Manufacturers - Specialty & Generic · Healthcare · United States
0.71
close · 2026-10-30
value
16
cheaper than peers16
quality
4
stronger fundamentals4
ranked against
Drug Manufacturers - Specialty & Generic
value
quality
41 peerswide variation
Value inputs
| measure | company | vs peers |
| cash flow yield, latest year | 30.6% | 94 |
| price to sales | 0.89× | 91 |
| earnings yield, latest year | -2.8% | 38 |
| price to book | 7.68× | 24 |
| earnings yield, 2 years ago | -39.6% | 19 |
| cash flow yield, 2 years ago | -11.9% | 18 |
| earnings yield, 1 year ago | -46.7% | 13 |
| cash flow yield, 3 years ago | -37.4% | 11 |
| cash flow yield, 1 year ago | -20.8% | 6 |
| earnings yield, 3 years ago | -72.2% | 1 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | -5.5% | 34 |
| revenue growth | -21.4% | 15 |
| debt to equity | 796.2% | 13 |
| return on equity | -109.4% | 10 |
4 of 4 measures available
Facts
| market cap | $196M |
| free cash flow | $33.6M |
| employees | 194 |
| first trade | 2014-03-20 |
| next earnings | 2026-11-05 |
| fundamentals updated | 2026-08-13 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -0.02 | -0.33 | -0.28 | -0.51 |
| free cash flow | $59.9M | -$40.7M | -$23.4M | -$73.3M |
| net income | -$5.3M | -$69.4M | -$51.9M | -$94.2M |
| revenue | $236.2M | $160.2M | $194.6M | $292.5M |
| unusual items | -$3.1M | -$905,000 | -$705,000 | -$16.8M |